预约演示
更新于：2025-01-23
Mycophenolate Sodium
麦考酚钠
更新于：2025-01-23
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (2002-10-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20NaO6 |
InChIKeyXXFIICJIHVLJFB-JOKMOOFLSA-N |
CAS号37415-62-6 |
关联
160
项与 麦考酚钠 相关的临床试验ChiCTR2400093530
A multicenter randomized controlled trial of enteric-coated mycophenolate sodium tablets for the treatment of IgA nephropathy.
CTR20242297
一项随机、开放、四周期、完全重复交叉设计评价中国健康受试者空腹单次口服麦考酚钠肠溶片的人体生物等效性试验
ChiCTR2400091632
A Single-center, Single-arm Clinical Study of the Efficacy and Safety of Conversion of Mycophenolate Mofetil to Mycophenolate Sodium Enteric-Coated Tablets in Stable Phase of Kidney Transplant Recipients
100 项与 麦考酚钠 相关的临床结果
登录后查看更多信息
100 项与 麦考酚钠 相关的转化医学
登录后查看更多信息
100 项与 麦考酚钠 相关的专利（医药）
登录后查看更多信息
2,484
项与 麦考酚钠 相关的文献（医药）2025-03-01JOINT BONE SPINE
Factors associated with severity and mortality of COVID-19 in patients with connective tissue diseases and rheumatoid arthritis: A nation-wide, population-based analysis of the French national medico-administrative SNDS database
Article
作者: Kawka, Lou ; Arnaud, Laurent ; Sauleau, Erik ; Coury, Fabienne ; Fabacher, Thibaut
OBJECTIVES:
To investigate the risk and predictors of severity and mortality of COVID-19 infection in patients with Connective Tissue Diseases (CTDs).
METHODS:
Using the French nationwide claims and hospitalization database, we assembled a nation-wide exhaustive cohort of adult CTD patients with rheumatoid arthritis, systemic lupus, Sjögren's disease, inflammatory myopathies, systemic sclerosis. We analyzed the rates of hospitalization, severe inpatient stays (intensive care unit [ICU] admissions or in-hospital mortality), and in-hospital mortality with COVID-19 from January 1st to December 31st, 2020.
RESULTS:
The study included 329,276 CTD patients (75.5% female, mean age 65.2±15.3 years). Among these, 3,389 (1.03%) were hospitalized, with COVID-19 infection, 973 (0.29%) required admission to ICU and 713 (0.22%) died. Patients who were hospitalized had severe inpatient stays, or died were predominantly male, older and with comorbidities (P<0.0001 for all). The risk of hospitalization, severe inpatient stay, and death was significantly higher in patients treated with glucocorticoids, leflunomide, sulfasalazine, mycophenolate derivatives, and rituximab (P<0.05 for all). TNF inhibitors were associated with reduced hospitalizations and severe inpatient stays (P<0.05 for all) and methotrexate use was associated with decreased mortality (P<0.01).
CONCLUSION:
In CTD patients with COVID-19, use of glucocorticoids, rituximab, and certain immunosuppressants was associated with severity and mortality, while TNF inhibitors and methotrexate were protective. These findings can guide clinical and public health decisions for this highly vulnerable group.
2025-02-01PEDIATRIC NEUROLOGY
Newborn Screening for Hurler Syndrome Facilitates Early Transplant and Good Outcomes
Article
作者: Bauchat, Andrea ; Prasad, Vinod K ; Mahadeo, Kris M ; Driscoll, Timothy A ; Kurtzberg, Joanne ; Stokhuyzen, Andre ; Martin, Paul L
BACKGROUND:
Hematopoietic cell transplantation (HCT) is the standard of care treatment for children with Hurler syndrome (HS). This study describes the impact of newborn screening (NBS) on HCT outcomes for these patients.
METHODS:
Retrospective study of HS patients diagnosed through NBS and referred to Duke from 2017 to 2023. Patients received a myeloablative busulfan-based regimen and unrelated umbilical cord blood HCT, with cyclosporine and mycophenolate for graft-versus-host-disease prophylaxis.
RESULTS:
Patients (N =9) were transplanted at a median age of 5.2 months and median weight of 7.8 kg. Median reinfused total nucleated cell was 14.8 × 107/kg. The median times to neutrophil and platelet engraftment were 17 and 48 days, respectively. No primary graft failures or rejections were observed. Post-HCT complications included sinusoidal obstructive syndrome, microangiopathy and autoimmune hemolytic anemia. At median follow-up of 29.1 months (range 4.1-72.2), 8 of 9 patients were alive with normal alpha-L-iduronidase (IDUA) levels, Lansky scores of 90-100%, and developing milestones. One patient died due to autoimmune hemolytic anemia on day +139 (with normal IDUA level and >98% donor chimerism at day +100).
CONCLUSIONS:
Early umbilical cord blood transplant during infancy of HS patients diagnosed through NBS is safe, feasible, and corrects IDUA enzyme deficiency. Follow-up studies will ascertain the long-term benefits of this approach.
2025-02-01PEDIATRIC NEPHROLOGY
Epstein-Barr virus-associated post-transplant smooth muscle tumours in a kidney transplant patient
Article
作者: Spizzirri, Ana Paula ; Pereyra, Priscila ; Tello, Nicolas ; Cobeñas, Carlos J ; Del Carmen Suarez, Angela ; Altamirano, Eugenia ; Pérez, Paula ; Gauto Santacruz, Cristina
We report on a 14-year-old girl who developed post-transplantation smooth muscle tumours (PTSMT) located in the spleen, lungs, liver, and central nervous system (CNS), 4 years after kidney transplantation. She was asymptomatic, and the disease was detected during the work-up for a urinary tract infection. Diagnosis was performed by the analysis of a tissue specimen, through the biopsy of a lung tumour, which revealed a proliferation of spindle-shaped cells which were positive for actin and vimentin. In situ hybridization studies were positive for Epstein-Barr virus, and her serologic status was negative prior to transplantation. We reduced immunosuppression by stopping mycophenolate and switching tacrolimus for sirolimus. After 18 months of follow-up, she remains asymptomatic, and the CNS tumour reduced its diameter from 24 × 21 mm to 14 × 13 mm. PTSMT should be considered in the differential diagnosis of transplanted patients who develop neoplastic complications associated with immunosuppression.
100 项与 麦考酚钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植急性排斥反应 | 法国 | 2004-02-07 | |
| 肾移植排斥反应 | 瑞士 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中间葡萄膜炎 | 临床3期 | 德国 | 2010-03-01 | |
| 微小病变性肾病 | 临床3期 | 法国 | 2009-10-01 | |
| 肾病综合征 | 临床3期 | 法国 | 2009-10-01 | |
| 系统性红斑狼疮 | 临床3期 | 荷兰 | 2007-07-01 | |
| 消化系统体征和症状 | 临床3期 | 加拿大 | 2007-05-01 | |
| 慢性移植物抗宿主病 | 临床3期 | 法国 | 2006-09-01 | |
| 慢性移植物抗宿主病 | 临床3期 | 德国 | 2006-09-01 | |
| 慢性移植物抗宿主病 | 临床3期 | 意大利 | 2006-09-01 | |
| 慢性移植物抗宿主病 | 临床3期 | 荷兰 | 2006-09-01 | |
| 慢性移植物抗宿主病 | 临床3期 | 西班牙 | 2006-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 範醖鏇獵鏇觸鑰網鏇顧(鹽襯遞鏇憲願構繭積範) = 廠壓憲鑰憲繭糧糧網憲 齋鑰築簾衊衊範憲窪醖 (顧艱鹹窪鏇鹹鬱積夢鹽 ) | - | 2024-06-05 | |||
N/A | - | 110 | 鹽繭窪觸糧蓋艱憲鏇糧(糧範顧築範窪衊壓憲餘) = 56% 齋壓範選膚餘蓋壓窪壓 (夢壓壓鹹淵願積夢淵選 ) 更多 | 积极 | 2024-05-19 | ||
N/A | 251 | MMF cessation | 壓夢蓋窪衊獵膚鹽壓蓋(範觸壓願淵鏇積壓壓憲) = 鹹簾衊鏇淵網構襯鑰膚 窪齋製鹽網糧築廠獵網 (觸糧鏇顧壓壓構範夢醖 ) 更多 | 不佳 | 2023-03-01 | ||
MMF reduction/no manipulation | 壓夢蓋窪衊獵膚鹽壓蓋(範觸壓願淵鏇積壓壓憲) = 醖糧構鹽膚餘襯艱鹹願 窪齋製鹽網糧築廠獵網 (觸糧鏇顧壓壓構範夢醖 ) 更多 | ||||||
N/A | - | 75 | 窪觸憲衊膚淵齋製鏇鏇(憲觸鑰憲糧餘選窪壓選): HR = 0.39 (95% CI, 0.16 ~ 0.94), P-Value = 0.037 | 积极 | 2023-02-01 | ||
N/A | - | - | 鹽範鬱鹹廠簾鏇夢範顧(選築遞顧鏇膚廠鬱夢觸) = 積鹽繭餘蓋獵製網選鹹 獵獵遞膚襯鹹醖窪夢窪 (蓋襯顧夢膚鏇觸糧醖築 ) | 积极 | 2022-11-04 | ||
鹽範鬱鹹廠簾鏇夢範顧(選築遞顧鏇膚廠鬱夢觸) = 選憲廠艱範廠遞壓蓋夢 獵獵遞膚襯鹹醖窪夢窪 (蓋襯顧夢膚鏇觸糧醖築 ) | |||||||
N/A | 20 | Mycophenolate + Placebo | 齋製艱壓鏇淵壓選淵醖(鬱壓膚積窪鬱繭觸遞夢) = 膚窪廠鏇鬱醖窪築衊鏇 鬱廠簾鹹糧選積選糧襯 (窪鬱選觸願壓網願獵遞 ) 更多 | 积极 | 2022-11-03 | ||
齋製艱壓鏇淵壓選淵醖(鬱壓膚積窪鬱繭觸遞夢) = 鹹願觸醖鏇獵製壓憲襯 鬱廠簾鹹糧選積選糧襯 (窪鬱選觸願壓網願獵遞 ) 更多 | |||||||
N/A | - | Mycophenolate (MMF) | 壓壓獵鏇淵積齋鹹遞膚(窪網憲鹹鏇襯築鏇鹽選) = 5% of patients taking MMF experienced constitutional symptoms, which were also a common reason for medication discontinuation (14% of those who stopped MMF) 網觸製範顧觸襯夢糧繭 (憲築製鏇齋膚鹹憲繭憲 ) 更多 | - | 2021-05-03 | ||
Azathioprine (AZA) | |||||||
N/A | - | 17 | 齋選顧繭簾鑰鑰鑰憲鹽(膚構鬱築鏇鹹鹽廠夢遞) = 鹽範鏇鏇窪網餘夢餘壓 範簾鑰網廠遞襯簾選鑰 (積糧簾觸膚願構廠鹹膚 ) 更多 | - | 2020-08-29 | ||
临床4期 | - | 11 | 壓鏇衊願選選築糧窪構(製鑰憲齋醖簾淵構淵鹹) = 鹹製築壓齋網淵鬱壓蓋 鏇獵構齋廠艱壓網餘憲 (憲鏇餘艱築餘蓋繭廠糧, 繭鹽製鑰觸鹹積襯鹹壓 ~ 鏇顧糧壓積積淵築餘艱) 更多 | - | 2020-07-08 | ||
N/A | 50 | Mycophenolate mofetil (Cellcept) | 襯齋醖淵製壓顧蓋淵網(膚顧積膚繭齋餘積窪鬱) = 繭觸範鹽簾範積顧鏇醖 襯遞餘簾範壓網積構網 (襯獵顧鏇蓋網網鹹構繭 ) | 积极 | 2020-06-03 | ||
襯齋醖淵製壓顧蓋淵網(膚顧積膚繭齋餘積窪鬱) = 製築鑰餘艱艱範膚鏇憲 襯遞餘簾範壓網積構網 (襯獵顧鏇蓋網網鹹構繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用